1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2014

Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2014

  • August 2014
  • -
  • Global Markets Direct
  • -
  • 76 pages

Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2014’, provides an overview of the Mycobacterium Tuberculosis Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mycobacterium Tuberculosis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mycobacterium Tuberculosis Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mycobacterium Tuberculosis Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Mycobacterium Tuberculosis Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Mycobacterium Tuberculosis Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Mycobacterium Tuberculosis Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Mycobacterium Tuberculosis Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Mycobacterium Tuberculosis Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2014
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Mycobacterium Tuberculosis Infections Overview 8
Therapeutics Development 9
Pipeline Products for Mycobacterium Tuberculosis Infections - Overview 9
Pipeline Products for Mycobacterium Tuberculosis Infections - Comparative Analysis 10
Mycobacterium Tuberculosis Infections - Therapeutics under Development by Companies 11
Mycobacterium Tuberculosis Infections - Therapeutics under Investigation by Universities/Institutes 13
Mycobacterium Tuberculosis Infections - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Mycobacterium Tuberculosis Infections - Products under Development by Companies 18
Mycobacterium Tuberculosis Infections - Products under Investigation by Universities/Institutes 19
Mycobacterium Tuberculosis Infections - Companies Involved in Therapeutics Development 20
Shionogi and Co., Ltd. 20
AstraZeneca PLC 21
GlaxoSmithKline plc 22
Novartis AG 23
Oragenics, Inc. 24
Archivel Farma S.L. 25
NovoBiotic Pharmaceuticals, LLC 26
Spring Bank Pharmaceuticals, Inc. 27
Bioversys AG 28
Univalue Valorizacion, S.L. 29
GlobalAcorn 30
Mycobacterium Tuberculosis Infections - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
RUTI - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
ID-93 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
MU-1140 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
BV-6481 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Small Molecule for Staphylococcus Aureus Infections and Mycobacterium Tuberculosis Infections - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Small Molecules to Inhibit Gyrase for Mycobacterium Tuberculosis Infections - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
rAMtb-SIVgag Vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
NITD-349 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Small Molecules to Inhibit Structural Protein FtsZ for Bacterial Infections - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
Small Molecules for Bacterial and Viral Infections - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
SB-9922 - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Novo-23 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Small Molecules to Inhibit DprE1 for Mycobacterium Tuberculosis - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Thuggacine - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
KKL-35 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Small Molecule for Tuberculosis - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
Small Molecule 2 for Tuberculosis - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
Small Molecules to Inhibit CysK1 for Tuberculosis - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
GA-3MEP-TB - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
Small Molecules for Mycobacterium Tuberculosis Infections - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
Small Molecules for Mycobacterium Tuberculosis - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
Small Molecules for Infectious Disease - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
Small Molecules for Multiresistant Mycobacterium Tuberculosis Infections - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
Synthetic Peptide for Bacterial Infections - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
Mycobacterium Tuberculosis Infections - Recent Pipeline Updates 68
Mycobacterium Tuberculosis Infections - Dormant Projects 69
Mycobacterium Tuberculosis Infections - Product Development Milestones 70
Featured News and Press Releases 70
Dec 20, 2013: SIRTURO Receives Positive Opinion from the Committee for MedicinalProducts for Human Use as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis 70
Aug 01, 2013: Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infections with Pulmaquin and Lipoquin 70
Jun 17, 2013: Researchers Identify New Compound Effective Against Persistent And Drug-Resistant Tuberculosis 71
Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140 73
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 76
Disclaimer 76

List of Tables

Number of Products under Development for Mycobacterium Tuberculosis Infections, H2 2014 9
Number of Products under Development for Mycobacterium Tuberculosis Infections - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Comparative Analysis by Unknown Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Mycobacterium Tuberculosis Infections - Pipeline by Shionogi and Co., Ltd., H2 2014 20
Mycobacterium Tuberculosis Infections - Pipeline by AstraZeneca PLC, H2 2014 21
Mycobacterium Tuberculosis Infections - Pipeline by GlaxoSmithKline plc, H2 2014 22
Mycobacterium Tuberculosis Infections - Pipeline by Novartis AG, H2 2014 23
Mycobacterium Tuberculosis Infections - Pipeline by Oragenics, Inc., H2 2014 24
Mycobacterium Tuberculosis Infections - Pipeline by Archivel Farma S.L., H2 2014 25
Mycobacterium Tuberculosis Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2014 26
Mycobacterium Tuberculosis Infections - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2014 27
Mycobacterium Tuberculosis Infections - Pipeline by Bioversys AG, H2 2014 28
Mycobacterium Tuberculosis Infections - Pipeline by Univalue Valorizacion, S.L., H2 2014 29
Mycobacterium Tuberculosis Infections - Pipeline by GlobalAcorn, H2 2014 30
Assessment by Monotherapy Products, H2 2014 31
Number of Products by Stage and Target, H2 2014 33
Number of Products by Stage and Mechanism of Action, H2 2014 35
Number of Products by Stage and Route of Administration, H2 2014 37
Number of Products by Stage and Molecule Type, H2 2014 39
Mycobacterium Tuberculosis Infections Therapeutics - Recent Pipeline Updates, H2 2014 68
Mycobacterium Tuberculosis Infections - Dormant Projects, H2 2014 69

List of Figures

Number of Products under Development for Mycobacterium Tuberculosis Infections, H2 2014 9
Number of Products under Development for Mycobacterium Tuberculosis Infections - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Products, H2 2014 16
Assessment by Monotherapy Products, H2 2014 31
Number of Products by Top 10 Target, H2 2014 32
Number of Products by Stage and Top 10 Target, H2 2014 33
Number of Products by Top 10 Mechanism of Action, H2 2014 34
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 35
Number of Products by Top 10 Route of Administration, H2 2014 36
Number of Products by Stage and Top 10 Route of Administration, H2 2014 37
Number of Products by Top 10 Molecule Type, H2 2014 38
Number of Products by Stage and Top 10 Molecule Type, H2 2014 39

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.